The longevity biotechnology company NOVOS has released results from a randomized, double blind, placebo-controlled clinical trial of its flagship supplement NOVOS Core. This venture demonstrates statistically significant improvements in three distinct cardiovascular biomarkers associated with healthy aging — endothelial function, arterial flexibility, and systolic blood pressure.
The study relied on adults aged 40 and older without diagnosed heart disease and lasted over six months. The researchers concluded that individuals using NOVOS Core experienced a 2.9% improvement in flow-mediated dilation shortly after the first dose and sustained that benefit for half a year, while the placebo group showed no meaningful change. The improvement in arterial function was comparable to what published studies have shown from sustained high-intensity interval training, the reduction in pulse wave velocity matched or exceeded results from Mediterranean diet interventions and significant weight loss, and the 6.1 millimetres of mercury drop in systolic blood pressure occurred even though participants already had readings in the normal range.
Scientifically Proven Longevity Supplements
NOVOS Releases Study for NOVOS Core
Trend Themes
1. Clinically Validated Longevity Supplements - Emergence of supplements supported by randomized controlled trials is creating a new category where consumer health products carry measurable, peer-reviewed efficacy claims that compete with traditional therapies.
2. Biomarker-driven Health Personalization - Increasing reliance on specific cardiovascular biomarkers to assess intervention impact is enabling tailored regimens that differentiate offerings based on objective physiological outcomes.
3. Non-pharmaceutical Cardiovascular Interventions - Supplements and lifestyle-mimicking formulations demonstrating effects comparable to exercise or diet interventions are redefining non-drug approaches to blood pressure and arterial health management.
Industry Implications
1. Nutraceuticals - A shift toward evidence-backed formulations is positioning nutraceutical companies to encroach on clinical markets by delivering regulated products with quantifiable health endpoints.
2. Digital Health Diagnostics - Wearables and at-home testing platforms that track endothelial function and arterial stiffness are becoming integral to validating and personalizing supplement efficacy.
3. Preventive Cardiology - Clinically effective supplements that lower systolic blood pressure in normotensive adults are influencing preventive care models and risk-reduction strategies within cardiology practices.